Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 132 of the 135 references it cites were found in a registry or an index.

Apolipoprotein C-III: understanding an emerging cardiovascular risk factor

Abstract

The concurrence of visceral obesity, insulin resistance and dyslipidaemia comprises the concept of the metabolic syndrome. The metabolic syndrome is an escalating problem in developed and developing societies that tracks with the obesity epidemic. Dyslipidaemia in the metabolic syndrome is potently atherogenic and, hence, is a major risk factor for CVD (cardiovascular disease) in these subjects. It is globally characterized by hypertriglyceridaemia, near normal LDL (low-density lipoprotein)-cholesterol and low plasma HDL (high-density lipoprotein)-cholesterol. ApoC-III (apolipoprotein C-III), an important regulator of lipoprotein metabolism, is strongly associated with hypertriglyceridaemia and the progression of CVD. ApoC-III impairs the lipolysis of TRLs [triacylglycerol (triglyceride)-rich lipoproteins] by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. In the circulation, apoC-III is associated with TRLs and HDL, and freely exchanges among these lipoprotein particle systems. However, to fully understand the complex physiology and pathophysiology requires the application of tracer methodology and mathematical modelling. In addition, experimental evidence shows that apoC-III may also have a direct role in atherosclerosis. In the metabolic syndrome, increased apoC-III concentration, resulting from hepatic overproduction of VLDL (very-LDL) apoC-III, is strongly associated with delayed catabolism of triacylglycerols and TRLs. Several therapies pertinent to the metabolic syndrome, such as PPAR (peroxisome-proliferator-activated receptor) agonists and statins, can regulate apoC-III transport in the metabolic syndrome. Regulating apoC-III metabolism may be an important new therapeutic approach to managing dyslipidaemia and CVD risk in the metabolic syndrome.

Overview

Integrity signals

Registry

Crossref · 10.1042/cs20070308

Cites

132 of 132 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 135 references

Research works printed but not linked: 4

  1. Assmann, 1998, The emergence of triglycerides as a significant independent risk factor in coronary artery disease, Eur. Heart J., 19, M8
  2. Ginsberg, 1986, Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceriderich lipoproteins by lipoprotein lipase in vivo, J. Clin. Invest., 78, 1287, 10.1172/JCI112713 · DOI · Paper page
  3. Sundaram, 2007, New insights into the roles of apolipoprotein C-III in stimulating the production of hepatic VLDL, Arteriosclerosis Thrombosis Vascular Biology Annual Conference, P142
  4. Clavey, 1995, Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII and E, Arterioscler. Thromb. Vasc. Biol., 15, 963, 10.1161/01.ATV.15.7.963 · DOI · Paper page

Cited by

See all 282

Metadata

Authors
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F.
Affiliations
The University of Western Australia (AU)
Venue
Clinical Science
Published
2008-04-14
Volume
114
Issue
10
Pages
611-624
ISSN
  • 0143-5221 (ISSN-L)
  • 1470-8736
OpenAlex
W2037283919
Cited by
282
References
135
Citations by year
2026: 7 · 2025: 10 · 2024: 12 · 2023: 11 · 2022: 12 · 2021: 16 · 2020: 18 · 2019: 22 · 2018: 16 · 2017: 16 · 2016: 25 · 2015: 18 · 2014: 17 · 2013: 25 · 2012: 10
FWCI
2.38
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Science (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
Funders
National Institute of Biomedical Imaging and Bioengineering (P41EB001975)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
apolipoprotein C-III, metabolic syndrome, hypertriglyceridemia, dyslipidemia, cardiovascular risk, triglyceride-rich lipoproteins, lipoprotein lipase inhibition, atherosclerosis, PPAR agonists, statins, lipoprotein metabolism
MeSH terms
Animals, Humans, Insulin Resistance, Intestinal Mucosa, Liver, Risk Factors, Triglycerides, Hypertriglyceridemia, Metabolic Syndrome, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. https://app.cochat.ai/papers/10.1042/cs20070308
The paper
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008). Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clinical Science. https://doi.org/10.1042/cs20070308

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.